Hugel is accelerating its push into the Indonesian market.
Hugel said on April 27 it recently conducted a training program on its botulinum toxin product Letybo (marketed domestically as Botulax) for about 200 local medical professionals and industry participants in Indonesia.
The event was held as part of the annual “Parvus Summit,” organized by its local distributor Parvus.
As a domestic medical expert (HCP), Park Young-jin, director of Songdo Obliv Clinic, participated as the keynote speaker and introduced the advantages of Letybo’s narrow diffusion profile.
Park said, “Letybo allows for precise treatment targeting only the desired area, which can reduce the likelihood of side effects.”
Hugel, which entered the Indonesian market in September 2024, expects the event to enhance local medical professionals’ understanding and utilization of Letybo, while strengthening brand loyalty.
Hugel CEO Jang Doo-hyun said, “Indonesia is not only a populous country but also one with solid economic growth, and its medical aesthetics market is expanding rapidly,” adding, “We will strengthen Letybo’s competitiveness and expand brand awareness through continuous academic exchange with local medical professionals.”
